SCHMITT DANIEL M purchased $50K of ACTU
SCHMITT DANIEL M (President, CEO and Director) purchased 140,844 shares of ACTUATE THERAPEUTICS, INC. (ACTU) at $0.36 on 2026-10-28.
How this was made
The 30-second read
Why it matters
The filing provides fresh insight into insider sentiment, which can be a factor in short-term price movement.
Market read
A modest insider purchase may generate slight positive bias but is unlikely to drive major price moves.
What to watch
The low transaction size relative to market cap may limit price impact.
Background
Actuate Therapeutics filed a Form 4 reporting an insider purchase by its CEO.
Ticker impact
Form 4 shows CEO Daniel Schmitt purchased 140,844 shares for $49,999, increasing his stake to 442,560 shares.
potential modest upside as market prices in insider confidence
The purchase is modest in dollar terms but represents a sizable increase in ownership by the CEO, which may be viewed favorably by investors.
Market effects
Limited impact on the broader biotech sector.
No significant regional effect.
Minimal global relevance.
Counterpoint
The purchase may be a routine portfolio rebalancing rather than a strong bullish signal.
Key entities
- PersonDaniel Schmitt
President, CEO and Director of Actuate Therapeutics
- CompanyActuate Therapeutics, Inc.
Biotech firm listed on US exchanges under ticker ACTU